Multiple myeloma clinical trials in Missouri

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Gammagard to prevent infections in multiple myeloma

This study tests if adding Gammagard (a type of antibody therapy) to your multiple myeloma treatment with Tecvayli can help prevent serious infections. You may qualify if you recently started Tecvayli and are still responding to it.

Cemsidomide and dexamethasone for relapsed/refractory multiple myeloma

This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.

Study of Inobrodib, Pomalidomide, and Dexamethasone for Multiple Myeloma

This trial tests a new combination of three drugs—inobrodib, pomalidomide, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug adds benefit for patients who have tried other therapies.

IL-7 treatment after CAR-T therapy for multiple myeloma

This trial tests whether a drug called NT-I7 (a lab-made immune booster) can help people with multiple myeloma who have already received a CAR-T cell therapy called cilta-cel. It's for patients whose myeloma has come back or hasn't responded well to treatment.

AZD0305 alone or with other drugs for multiple myeloma

This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.

New treatment combo study for newly diagnosed multiple myeloma

This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.

Etentamig vs standard therapy for relapsed myeloma

This trial tests a new IV treatment called etentamig compared to standard therapies for people with multiple myeloma that has come back or stopped responding. It may be an option if you've already tried at least two different treatments, including common drug classes.

Testing CS1 CAR-T for multiple myeloma

This study tests a new cell therapy called CS1 CAR-T, which helps your immune system attack myeloma cells that still grow after several other treatments. It's for people who have already tried at least three different types of therapy.

CAR T cell therapy for multiple myeloma

This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.

Study of etentamig and a CELMoD drug for relapsed multiple myeloma

This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.

Selinexor after CAR-T for high-risk multiple myeloma

This trial tests if the drug selinexor can help prevent multiple myeloma from coming back after CAR-T cell therapy. It is for people with high-risk or persistent myeloma who have already received a specific CAR-T treatment called Carvykti.

Sonrotoclax with steroid and other drugs for multiple myeloma

This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.

Belantamab mafodotin combinations for relapsed multiple myeloma

This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.

Study of AZD0120 for multiple myeloma patients

This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.

New drug combo for multiple myeloma without stem cell transplant

This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.

Testing interleukin-7 after stem cell transplant for myeloma

This study tests whether a drug called interleukin-7 (CYT107) can help your immune system recover faster and clear myeloma cells better after a stem cell transplant. You would receive CYT107 injections after your transplant, and the study will check if this improves your long-term outcome.

Carvykti with special radiation and chemo for kidney patients

This trial tests adding total body radiation and a chemotherapy drug (cyclophosphamide) before the standard Carvykti cell therapy for multiple myeloma patients who have kidney problems. The goal is to see if this approach is safe and effective for people with reduced kidney function.

New treatment for high-risk myeloma before transplant

This study tests a new treatment combination for people with high-risk multiple myeloma who are newly diagnosed and healthy enough for a stem cell transplant. The goal is to see if the treatment can improve outcomes compared to standard therapy.

Study of elranatamab for multiple myeloma that returned after other treatments

This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.

Isatuximab with carfilzomib and dexamethasone for multiple myeloma

This trial tests a new combination of drugs (isatuximab, carfilzomib, and dexamethasone) given as shots under the skin for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if this mix works better than previous options.

Newly diagnosed multiple myeloma test of combination therapy

This Phase 3 trial tests a combination treatment approach for adults with newly diagnosed multiple myeloma, focusing on response and deeper remission. It may help by improving how well the disease is controlled early and measuring results beyond standard tests.

Continuing isatuximab treatment for multiple myeloma

This study allows people with multiple myeloma who are already benefiting from the drug isatuximab in an earlier clinical trial to keep receiving it after that trial ends. It is an extension study, meaning you can continue your treatment without interruption.

Drug combinations for newly diagnosed myeloma without transplant

This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.